trial

Promoting Cognitive Health in Schizophrenia

NCTId NCT05661448
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Recruiting
Enrollment 390 (estimated)
Sponsored by Douglas Mental Health University Institute
Primary completion 2029-08-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Recruiting
Enrollment
390 (estimated)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
None
Start
2023-04-15
Primary completion
2029-08-31
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
Cognitive RemediationMetacognitive training

Sponsors

Douglas Mental Health University InstituteLead Sponsor
Canadian Institutes of Health Research (CIHR)Collaborator
McGill UniversityCollaborator

Investigators

1
Martin LepagePrincipal Investigator

Sites

5 total
Vancouver, CanadaKingston, CanadaOttawa, CanadaToronto, CanadaMontreal, Canada

Facts & assertions

4 sourced
Enrollment
390
Phase
NA
Primary Completion Date
2029-08-31
Status
RECRUITING
relationships
The graph out of here
drug
Cognitive Remediation
drug
Metacognitive training
drug
lead_sponsor
Douglas Mental Health University Institute
company
collaborator
Canadian Institutes of Health Research (CIHR)
company
McGill University
company
indication
Schizophrenia
indication
Schizophrenia
indication
Cognition
indication
investigator
Martin Lepage
person